Hytrin 5

Terazosin, the active ingredient in Hytrin 5, is a alpha-1 adrenergic blocker presented as an oral tablet for oral use. It is employed to lower high blood pressure and to relieve urinary obstruction caused by an enlarged prostate in adult patients. The product conforms to European Union quality standards and is distributed under a prescription‑only status.

GNH USA supplies Hytrin 5 as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable logistics and regulatory compliance globally.

Terazosin is used to treat conditions related to vascular tone and prostate smooth‑muscle tone. - Hypertension: reduces systemic vascular resistance, helping to lower elevated blood pressure. - Benign prostatic hyperplasia: relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms. - Lower urinary tract symptoms: alleviates urgency, frequency, and nocturia associated with prostate enlargement.

Terazosin may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Headache. - Fatigue or tiredness. - Nasal congestion or runny nose. - Peripheral edema. - Orthostatic hypotension.

Serious or Rare Side Effects: - Severe hypotension leading to fainting. - Syncope. - Priapism (prolonged erection). - Acute heart failure exacerbation. - Significant liver enzyme elevation. - Severe allergic reactions such as rash, swelling, or anaphylaxis.

Before initiating terazosin therapy, several safety considerations should be observed. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Dose titration: start low and increase gradually as directed by the prescriber. - Concurrent antihypertensives: assess risk of additive blood pressure lowering. - Renal or hepatic impairment: adjust dose or monitor closely. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Terazosin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors: may increase terazosin plasma levels, risking hypotension. - Other alpha‑blockers: additive vasodilatory effect leading to severe hypotension. - Sildenafil and other PDE5 inhibitors: can cause profound blood pressure drops.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension, monitor volume status. - Antihypertensive agents (ACE inhibitors, ARBs, beta‑blockers): may require dose adjustment. - Alcohol: can increase dizziness and hypotensive effects.